Legend names founder Frank Zhang as chief executive officer
Aug 2 (Reuters) - Legend Biotech Corp LEGN.O, a cell therapy unit of Hong Kong-listed Genscript Biotech Corp 1548.HK, said on Sunday it appointed Frank Zhang as chief executive officer and that he will step down as Genscript's CEO.
Outgoing Legend CEO Yuan Xu resigned for personal reasons, according to the U.S.-based Biotech firm, adding that Xu also resigned from Legend's board.
Zhang, who founded Legend in 2014, has been the board chairman for past five years. He will continue in the position and take charge as CEO effective immediately.
The leadership change came about two months after the firm's U.S. stock market debut. Legend raised $423.8 million in the initial public offering.
(Reporting by Maria Ponnezhath in Bengaluru; Editing by Steve Orlofsky)
((Maria.Ponnezhath@thomsonreuters.com; +91 8061822749;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This Story
LEGNLatest Markets Videos
Explore US Markets
ExploreMost Popular
- Tesla removed from S&P 500 ESG index on autopilot, discrimination concerns
- US STOCKS-Wall Street ends sharply lower as Target and growth stocks sink
- Powell says Fed to 'keep pushing' rates higher until clear inflation is falling
- Buffett's Berkshire buys Citigroup and several other stocks, slashes Verizon